中医综合方案对心脏病基础AIS患者疗效评价及益脑康相关实验研究
|
摘要
背景：
中风(stroke)是指一切在供应脑组织血液的血管壁病变或血流障碍的基础上发生的缺血或出血及其引起的短暂或持久、局部或弥漫的脑损害。中风病具有高发病率高致残率、高致死率、高复发率,低治愈率等特点。我国每年有195万新发生的卒中病人,每年有156万人死于脑卒中,生存的脑卒中病人达500万-700万人。对于发展中的中国,这无疑是个沉重的社会及家庭负担。因此对中风病防治的研究一直是医疗领域研究的热点和重点。脑血管疾病和心脏病排在人类致死病因的前三位,并且心脏病是中风的一个危险因素,二者在病理生理机制方面也有诸多的共同之处。探讨二者的关系一直是临床及基础研究的热门课题。中医药对疾病的治疗具有多靶点,多方位的特点。脑脉1号是广东省中医院刘茂才教授治疗中风病多年的经验方,其针对中风阴类证的病机气虚血瘀,痰瘀阻络而设,具有益气活血、化痰通络的作用,已被开发为广东省中医院院内制剂并广泛应用于临床,并且临床疗效显著,深得患者的好评,深入了解其治疗中风的作用机理意义重大。
目的：
本课题临床研究部分是在国家科技部十五攻关课题“急性缺血中风辨证规范与疗效评价的示范研究”(任务书编号：2004BA721A02)数据库的基础上进行。拟一方面从中医综合方案与基础治疗方案治疗前后中风后患者神经功能缺损、残障和生存质量、中医症征相关积分等多角度评价中医综合方案对心脏病基础急性缺血性中风患者疗效情况,另一方面从前后时点各种积分的对比评价中医综合方案治疗对心脏病基础的急性缺血中风患者的疗效。动物实验部分拟就益脑康对动脉粥样硬化及动脉粥样硬化基础上的急性缺血性中风SD大鼠的血脂、ox-LDL、ICAM-1、VEGF等指标进行研究,以期部分阐述其作用机制。方法：
本研究临床部分利用SPSS13.0统计分析软件对十五攻关课题“急性缺血中风辨证规范与疗效评价的示范研究”数据库中采用中医综合治疗方案和西医基础治疗方案的具有心脏病基础的急性缺血性中风阴类证患者的心脏病罹患情况进行描述性统计,对其BI评分、GCS评分、NIHSS评分及中医方面的相关评分情况进行统计学分析,并对心脏病基础的急性缺血性中风阴类证患者中采用中医综合治疗方案的各时点的各种评分进行前后配对对比分析。
动物实验部分选取体重180g±20g SD雄性大鼠115只,采用随机数字表将115只大鼠随机分为A组(正常组)15只；B～E组(模型组)100只。其中C组为动脉粥样硬化组、D组为复合模型组、B组为益脑康预防组、E组为益脑康治疗组、F组为立普妥治疗组)。B、C、D、E、F组共100只大鼠,在第8天开始一次性VD3腹腔注射后开始给养高脂饲料复制AS模型,第65天,除C组外均采用ET-1 MCA附近注射法复制AIS模型。观察造模后大鼠的一般状态,第74天,每组大鼠随机抽取10只采血采用酶联免疫吸附试验(ELISA法)测定血脂及ox-LDL、ICAM、VEGF浓度,每组2只采集脑组织HE染色观察脑组织病理改变情况。
结果：
临床研究：①明确有心脏疾病的病人达到了106例,占所有病例的19.73%,其中有明确的冠心病心绞痛及心肌梗塞病史的病人共计60例,占诊断明确的心脏病病人的56.60%,占纳入的缺血性中风阴类证病人的11.55%；②A、B两组心脏病基础的急性缺血性中风阴类证患者不同时点的NIHSS、BI、SS-QOL、中医症征积分症状严重程度评分、中医症征积分对生活影响评分、中医症征积分总分评分比较均无显著性差异(P>0.05)；③中医综合治疗方案对有无心脏病基础的两组各时点NIHSS评分组间比较,基线时两组间比较有统计学差异(P<0.05),7天、14天、21天时比较差异无统计学意义(P>0.05)。两组各时点BI评分组间比较在21天时差异无统计学意义(P>0.05),在60天、90天比较时差异有统计学意义(P<0.05)。两组各时点SS-QOL评分组间比较,在14天、21天比较两组差异均无统计学意义(P>0.05),但在60天、90天比较有显著性差异(P<0.05)。两组各时点中医症征积分症状严重程度评分组间比较,在0天、7天时差异无统计学意义(P>0.05),14天、21天、60天、90天时两组间比较差异均有统计学意义(P<0.05)；两组各时点中医症征积分对生活影响评分组间比较,在0天时差异无统计学意义(P>0.05),在7天、14天、21天、60天及90天时差异有统计学意义(P<0.05)；两组各时点中医症征积分总分评分组间比较,在0天、7天两组间比较差异无统计学意义(P>0.05),在14天、21天、60天、90天时差异有统计学意义(P<0.05)。④A组心脏病基础的急性缺血性中风阴类证患者NIHSS、BI、SS-QOL、中医症征积分症状严重程度评分、中医症征积分对生活影响评分、中医症征积分总分评分前后时点配对比较,差异均有统计学意义(P<0.05)。
实验研究：①预用益脑康组的血脂指标TCHO, TG、LDL、HDL、ApoA与动脉粥样硬化组相比均具有显著的统计学差异。预用益脑康组的ox-LDL、ICAM、VEGF水平与动脉粥样硬化组相比差异均具有统计学意义。且在降低TG、HDL上预用益脑康组及益脑康组与动脉粥样硬化组相比有统计学意义,而立普妥组未得出与前述两组相似的统计学意义。中药组与立普妥组相比在改善血脂相关指标方面没有得出统计学方面的差异,但预用中药组及益脑康组在降低TCHO、TG、LDL-C方面显示出与立普妥组在数值方面的优势。②预用益脑康组、益脑康组及立普妥组在降低TCHO、LDL-C及升高ApoA方面与动脉粥样硬化组及AIS组相比在统计学方面均有显著的差异；预用中药组及益脑康组在降低TCHO、TG、LDL-C方面显示出与立普妥组在数值方面的优势。预用益脑康组、益脑康组和立普妥组的ox-LDL水平与AS组及AS基础AIS组相比差异均具有显著的统计学意义(P<0.05)；预用益脑康组与动脉粥样硬化组的ICAM相比差异具有显著的统计学意义(P<0.05),预用益脑康组、益脑康组及立普妥组的ICAM水平与AIS组相比差异具有显著的统计学意义(P<0.05)；预用益脑康组、益脑康组和立普妥组的VEGF水平与动脉粥样硬化组和AIS组相比差异均具有显著的统计学意义(P<0.05)。
临床研究：①本课题的卒中患者中具有较高的冠心病患病率；②中医综合防治方案在改善缺血性中风阴类证患者的神经功能缺损、生活能力、残障、生存质量、中医症征积分等方面并未显示出与西医基础治疗方案的统计学差异；③心脏病基础的缺血性中风患者的临床症状在发病后的不同时点均重于无心脏病基础的患者；中医综合治疗方案对无心脏病基础的缺血性中风阴类证患者在前两周就可以得到较好的评分结果,但对心脏病基础的患者大多在两周后评分改善才趋于加快。说明由于心脏病的影响,有心脏病基础的患者需要干预较长的时间才能达到与无心脏病基础的病人一致的效果；④通过BI评分、GCS评分、NIHSS评分及中医症征积分等各方面积分的自身前后时点配对比较表明中医综合治疗方案对心脏病基础的急性缺血性中风阴类证患者具有良好的治疗效果。
实验研究：①益脑康可以通过降低TCHO、TG、LDL水平而调高具有保护性及对抗动脉粥样硬化作用的HDL、ApoA改善脂质代谢,并通过降低ox-LDL、ICAM、VEGF水平从而部分程度上阻止动脉粥样硬化的发展。②益脑康能显著降低AS基础的AIS大鼠的ox-LDL、VEGF、ICAM水平,推断益脑康对缺血性中风的治疗效果可能与调节血脂代谢及对动脉粥样硬化形成发展过程中的ox-VEGF、ICAM的抑制有关。
Background:
Stroke refers to brain ischemic or hemorrhage based on blood vessel wall lesion or blood flow disorders,which cause temporary or persistent、local or diffused brain damage. It is a kind of disease of high incidence、high morbidity、high mortality、high recurrence rate and low cured rate. China has 1.95 million of new stroke patients each year, and 1.56 million people died of stroke,5-7 million people survive of cerebral apoplexy. To a developing country, it is undoubtedly a heavy burden to the society and patients'family. Therefore the research of stroke prevention and therapy is always a hotspot in the medical field. Cerebrovascular disease and heart disease are ranked in the first three main causes of death, and heart disease is a risk factor for stroke. Cerebrovascular disease and cardiovascular disease have many common in the pathophysiological mechanisms. Exploring their clinical and basic relationship has been the hot topic all the while. TCM is a kind of medicine of curing disease from more capable of targets and aspects. YiNaokang is an experienced formula of Guangdong hospital of TCM's famous professor LiuMaocai for curing stroke,it has a function of supplementing qi and activating blood circulation eliminating phlegm and freeing channel and has been exploited to be the hospital's preparations and been widely used in clinical and clinical curative effect is distinct, consequently it is of great significance to further study its mechanism of curing stroke.
Objective:
This dissertation is made up of two parts, the first part was clinical research and the second was animal experiment. The clinical research part is based on the Ministry of Science and Technology's 10th five year science research project "Demonstration Research of Acute Ischemic Stroke's Syndrome Differentiation and Therapeutic Effect Evaluation" (NO.2004BA721A02)'s database. Its main purpose is to evaluate the TCM comprehensive plan's therapeutic effect on these acute ischemic stroke patients who once have heart disease through statistic their NIHSS、BI、SS-QOL score and SSTCM related scores and compared them with Western Medicine's foundational scheme. Animal experiments is designed to study how the YiNaokang affect the atherosclerosis SD mices'and AS based acute ischemic stroke SD mices'blood cholesterol、ox-LDL、ICAM-l、VEGF、etc, so as to explain its mechanism.
Method:
This study's clinical part based on the Ministry of Science and Technology's 10th five year science research project "Demonstration Research of Acute Ischemic Stroke's Syndrome Differentiation and Therapeutic Effect Evaluation" (NO.2004BA721A02)'s database, firstly analysis and describe the patients who has heart disease, then statistic their BI、NIHSS、SS-QOL score and SSTCM related scores to compare the therapeutic effect of TCM comprehensive treatment and western medicine's basic treatment, at the same time, pair the back and forth time of the different kinds of scores of TCM comprehensive treatment group's so as to evaluate the TCM comprehensive treatment's effect on them.
Animal experiments part:select male SD rats weighted 180g±20g, using random number way to divide them into A group (normal) 15;B-E group (model) 100, among them group C is atherosclerosis group、D is composite group、B is Yi Naokang foregoing group、E is YiNaokang group、F is lipitor group. At the 8th day the 100 rats of groupB、C、D、E、F would be given intraperitoneal injection of VD3 one-time and then begain to supply with high fat feed to copy AS model, at the 65th day, inject ET-1 near the MCA area except group C to copy AIS model. Observe the general condition of them, at the 74th,10 rats would be picked out randomly to draw blood so as to test (ELISA way) blood lipids and LDL、ox-LDL、ICAM、VEGF concentration, pick out 2 randomly from each group to observe the brain pathological change.
Result:
Clinical research:①Of all patients,106 patients have heart disease, occupied 19.73%,60 have coronary heart disease or angina or miocardial infarction, occupied 56.60% of all the patients with heart disease,11.55% of all the 537 patients;②NIHSS、BI、SS-QOL、TCM related scores of AIS patients with heart disease between A, B groups have no significant statistical difference (P>0.05);③Treated with TCM comprehensive method, between the AIS patients with and without heart disease, the NIHSS scores have significant statistical difference(P<0.05) at the baseline, have no significant statistical difference on the day 7th、14th、21th; the BI scores have significant statistical difference (P<0.05) on the day 60th、90th, have no significant statistical difference on the 21th day (P>0.05);SS-QOL score have no significant statistical difference on the 14th、21th day (P>0.05), have significant statistical difference(P<0.05) on the day 60th、90th; SSTCM-Severity score have no significant statistical difference on the 0th、7th day (P>0.05), have significant statistical difference(P<0.05) on the day 14th、21th、60th、90th; SSTCM-Influence on day-life have no significant statistical difference on the 0th day (P>0.05), have significant statistical difference on the day7th、14th、21th、60th、90th (P<0.05); SSTCM-Total Score have no significant statistical difference on the 0th、7th day (P>0.05), have significant statistical difference on the day 14th,21th、60th、90th(P<0.05).④The different kinds of scores of AIS patients with heart disease in the TCM comprehensive treatment group compared back and forth time all have significant statistical difference.
Experiment research:①The YiNaokang foregoing group's TCHO、TG、LDL、HDL、ApoA are significant statistically different compared with AS group. The YiNaokang foregoing group's ox-LDL、ICAM、VEGF level are significant statistically different compared with AS group, and in lowering TG、HDL, YiNaokang foregoing group and YiNaokang group are significantly statistically different compared with AS group. Chinese traditional medicine showed numerical advantage over lipitor group in reducing TCHO and TG, LDL-C.②In reducing TCHO、TG、LDL-C and rising ApoA, the YiNaokang foregoing group、YiNaokang group and lipitor group have significant statistical difference compared with AS and AIS group. YiNaokang foregoing group、YiNaokang group showed numerical advantage over lipitor group in reducing TCHO、TG and LDL-C. YiNaokang foregoing group、YiNaokang group and lipitor group have statistical significant difference compared with AS group and AIS group in lowering ox-LDL. YiNaokang foregoing group、YiNaokang group and lipitor group have significant statistical difference compared with AIS group in lowering ICAM. YiNaokang foregoing group、YiNaokang group and lipitor group have significant statistical difference compared with AS group and AIS group in VEGF level.
Conclusion:
Clinical research:①Stroke patients with higher prevalence of coronary artery disease;②The TCM comprehensive treatment doesn't show significant statistical difference compared with western medicine's basic treatment on patients with and without heart disease;③The symptoms are obviously heavier on the AIS patients with heart disease than those without heart disease in different time; The TCM comprehensive treatment show good effect on AIS patients without heart disease in the first 2 weeks, but show effect on AIS patients with heart disease after the first 2 weeks.④The TCM comprehensive treatment show good effect on the AIS patients with heart disease through comparing the different kinds of scores of AIS patients with heart disease back and forth time.
Experiment research:①YiNaokang could prevents atherosclerosis devel-opment through reducing TCHO、LDL、TG、ox-LDL、ICAM、VEGF and rising HDL、ApoA level.②YiNaokang can significantly decrease AIS SD rats's ox-LDL, ICAM and VEGF level, so it is inferred that YiNaokang's treatment effect on ischemic stroke is probably through regulating lipid metabolism and lowering ox-LDL、VEGF、ICAM in the process of atherosclerosis'formation and development.
中风(stroke)是指一切在供应脑组织血液的血管壁病变或血流障碍的基础上发生的缺血或出血及其引起的短暂或持久、局部或弥漫的脑损害。中风病具有高发病率高致残率、高致死率、高复发率,低治愈率等特点。我国每年有195万新发生的卒中病人,每年有156万人死于脑卒中,生存的脑卒中病人达500万-700万人。对于发展中的中国,这无疑是个沉重的社会及家庭负担。因此对中风病防治的研究一直是医疗领域研究的热点和重点。脑血管疾病和心脏病排在人类致死病因的前三位,并且心脏病是中风的一个危险因素,二者在病理生理机制方面也有诸多的共同之处。探讨二者的关系一直是临床及基础研究的热门课题。中医药对疾病的治疗具有多靶点,多方位的特点。脑脉1号是广东省中医院刘茂才教授治疗中风病多年的经验方,其针对中风阴类证的病机气虚血瘀,痰瘀阻络而设,具有益气活血、化痰通络的作用,已被开发为广东省中医院院内制剂并广泛应用于临床,并且临床疗效显著,深得患者的好评,深入了解其治疗中风的作用机理意义重大。
目的：
本课题临床研究部分是在国家科技部十五攻关课题“急性缺血中风辨证规范与疗效评价的示范研究”(任务书编号：2004BA721A02)数据库的基础上进行。拟一方面从中医综合方案与基础治疗方案治疗前后中风后患者神经功能缺损、残障和生存质量、中医症征相关积分等多角度评价中医综合方案对心脏病基础急性缺血性中风患者疗效情况,另一方面从前后时点各种积分的对比评价中医综合方案治疗对心脏病基础的急性缺血中风患者的疗效。动物实验部分拟就益脑康对动脉粥样硬化及动脉粥样硬化基础上的急性缺血性中风SD大鼠的血脂、ox-LDL、ICAM-1、VEGF等指标进行研究,以期部分阐述其作用机制。方法：
本研究临床部分利用SPSS13.0统计分析软件对十五攻关课题“急性缺血中风辨证规范与疗效评价的示范研究”数据库中采用中医综合治疗方案和西医基础治疗方案的具有心脏病基础的急性缺血性中风阴类证患者的心脏病罹患情况进行描述性统计,对其BI评分、GCS评分、NIHSS评分及中医方面的相关评分情况进行统计学分析,并对心脏病基础的急性缺血性中风阴类证患者中采用中医综合治疗方案的各时点的各种评分进行前后配对对比分析。
动物实验部分选取体重180g±20g SD雄性大鼠115只,采用随机数字表将115只大鼠随机分为A组(正常组)15只；B～E组(模型组)100只。其中C组为动脉粥样硬化组、D组为复合模型组、B组为益脑康预防组、E组为益脑康治疗组、F组为立普妥治疗组)。B、C、D、E、F组共100只大鼠,在第8天开始一次性VD3腹腔注射后开始给养高脂饲料复制AS模型,第65天,除C组外均采用ET-1 MCA附近注射法复制AIS模型。观察造模后大鼠的一般状态,第74天,每组大鼠随机抽取10只采血采用酶联免疫吸附试验(ELISA法)测定血脂及ox-LDL、ICAM、VEGF浓度,每组2只采集脑组织HE染色观察脑组织病理改变情况。
结果：
临床研究：①明确有心脏疾病的病人达到了106例,占所有病例的19.73%,其中有明确的冠心病心绞痛及心肌梗塞病史的病人共计60例,占诊断明确的心脏病病人的56.60%,占纳入的缺血性中风阴类证病人的11.55%；②A、B两组心脏病基础的急性缺血性中风阴类证患者不同时点的NIHSS、BI、SS-QOL、中医症征积分症状严重程度评分、中医症征积分对生活影响评分、中医症征积分总分评分比较均无显著性差异(P>0.05)；③中医综合治疗方案对有无心脏病基础的两组各时点NIHSS评分组间比较,基线时两组间比较有统计学差异(P<0.05),7天、14天、21天时比较差异无统计学意义(P>0.05)。两组各时点BI评分组间比较在21天时差异无统计学意义(P>0.05),在60天、90天比较时差异有统计学意义(P<0.05)。两组各时点SS-QOL评分组间比较,在14天、21天比较两组差异均无统计学意义(P>0.05),但在60天、90天比较有显著性差异(P<0.05)。两组各时点中医症征积分症状严重程度评分组间比较,在0天、7天时差异无统计学意义(P>0.05),14天、21天、60天、90天时两组间比较差异均有统计学意义(P<0.05)；两组各时点中医症征积分对生活影响评分组间比较,在0天时差异无统计学意义(P>0.05),在7天、14天、21天、60天及90天时差异有统计学意义(P<0.05)；两组各时点中医症征积分总分评分组间比较,在0天、7天两组间比较差异无统计学意义(P>0.05),在14天、21天、60天、90天时差异有统计学意义(P<0.05)。④A组心脏病基础的急性缺血性中风阴类证患者NIHSS、BI、SS-QOL、中医症征积分症状严重程度评分、中医症征积分对生活影响评分、中医症征积分总分评分前后时点配对比较,差异均有统计学意义(P<0.05)。
实验研究：①预用益脑康组的血脂指标TCHO, TG、LDL、HDL、ApoA与动脉粥样硬化组相比均具有显著的统计学差异。预用益脑康组的ox-LDL、ICAM、VEGF水平与动脉粥样硬化组相比差异均具有统计学意义。且在降低TG、HDL上预用益脑康组及益脑康组与动脉粥样硬化组相比有统计学意义,而立普妥组未得出与前述两组相似的统计学意义。中药组与立普妥组相比在改善血脂相关指标方面没有得出统计学方面的差异,但预用中药组及益脑康组在降低TCHO、TG、LDL-C方面显示出与立普妥组在数值方面的优势。②预用益脑康组、益脑康组及立普妥组在降低TCHO、LDL-C及升高ApoA方面与动脉粥样硬化组及AIS组相比在统计学方面均有显著的差异；预用中药组及益脑康组在降低TCHO、TG、LDL-C方面显示出与立普妥组在数值方面的优势。预用益脑康组、益脑康组和立普妥组的ox-LDL水平与AS组及AS基础AIS组相比差异均具有显著的统计学意义(P<0.05)；预用益脑康组与动脉粥样硬化组的ICAM相比差异具有显著的统计学意义(P<0.05),预用益脑康组、益脑康组及立普妥组的ICAM水平与AIS组相比差异具有显著的统计学意义(P<0.05)；预用益脑康组、益脑康组和立普妥组的VEGF水平与动脉粥样硬化组和AIS组相比差异均具有显著的统计学意义(P<0.05)。
临床研究：①本课题的卒中患者中具有较高的冠心病患病率；②中医综合防治方案在改善缺血性中风阴类证患者的神经功能缺损、生活能力、残障、生存质量、中医症征积分等方面并未显示出与西医基础治疗方案的统计学差异；③心脏病基础的缺血性中风患者的临床症状在发病后的不同时点均重于无心脏病基础的患者；中医综合治疗方案对无心脏病基础的缺血性中风阴类证患者在前两周就可以得到较好的评分结果,但对心脏病基础的患者大多在两周后评分改善才趋于加快。说明由于心脏病的影响,有心脏病基础的患者需要干预较长的时间才能达到与无心脏病基础的病人一致的效果；④通过BI评分、GCS评分、NIHSS评分及中医症征积分等各方面积分的自身前后时点配对比较表明中医综合治疗方案对心脏病基础的急性缺血性中风阴类证患者具有良好的治疗效果。
实验研究：①益脑康可以通过降低TCHO、TG、LDL水平而调高具有保护性及对抗动脉粥样硬化作用的HDL、ApoA改善脂质代谢,并通过降低ox-LDL、ICAM、VEGF水平从而部分程度上阻止动脉粥样硬化的发展。②益脑康能显著降低AS基础的AIS大鼠的ox-LDL、VEGF、ICAM水平,推断益脑康对缺血性中风的治疗效果可能与调节血脂代谢及对动脉粥样硬化形成发展过程中的ox-VEGF、ICAM的抑制有关。
Background:
Stroke refers to brain ischemic or hemorrhage based on blood vessel wall lesion or blood flow disorders,which cause temporary or persistent、local or diffused brain damage. It is a kind of disease of high incidence、high morbidity、high mortality、high recurrence rate and low cured rate. China has 1.95 million of new stroke patients each year, and 1.56 million people died of stroke,5-7 million people survive of cerebral apoplexy. To a developing country, it is undoubtedly a heavy burden to the society and patients'family. Therefore the research of stroke prevention and therapy is always a hotspot in the medical field. Cerebrovascular disease and heart disease are ranked in the first three main causes of death, and heart disease is a risk factor for stroke. Cerebrovascular disease and cardiovascular disease have many common in the pathophysiological mechanisms. Exploring their clinical and basic relationship has been the hot topic all the while. TCM is a kind of medicine of curing disease from more capable of targets and aspects. YiNaokang is an experienced formula of Guangdong hospital of TCM's famous professor LiuMaocai for curing stroke,it has a function of supplementing qi and activating blood circulation eliminating phlegm and freeing channel and has been exploited to be the hospital's preparations and been widely used in clinical and clinical curative effect is distinct, consequently it is of great significance to further study its mechanism of curing stroke.
Objective:
This dissertation is made up of two parts, the first part was clinical research and the second was animal experiment. The clinical research part is based on the Ministry of Science and Technology's 10th five year science research project "Demonstration Research of Acute Ischemic Stroke's Syndrome Differentiation and Therapeutic Effect Evaluation" (NO.2004BA721A02)'s database. Its main purpose is to evaluate the TCM comprehensive plan's therapeutic effect on these acute ischemic stroke patients who once have heart disease through statistic their NIHSS、BI、SS-QOL score and SSTCM related scores and compared them with Western Medicine's foundational scheme. Animal experiments is designed to study how the YiNaokang affect the atherosclerosis SD mices'and AS based acute ischemic stroke SD mices'blood cholesterol、ox-LDL、ICAM-l、VEGF、etc, so as to explain its mechanism.
Method:
This study's clinical part based on the Ministry of Science and Technology's 10th five year science research project "Demonstration Research of Acute Ischemic Stroke's Syndrome Differentiation and Therapeutic Effect Evaluation" (NO.2004BA721A02)'s database, firstly analysis and describe the patients who has heart disease, then statistic their BI、NIHSS、SS-QOL score and SSTCM related scores to compare the therapeutic effect of TCM comprehensive treatment and western medicine's basic treatment, at the same time, pair the back and forth time of the different kinds of scores of TCM comprehensive treatment group's so as to evaluate the TCM comprehensive treatment's effect on them.
Animal experiments part:select male SD rats weighted 180g±20g, using random number way to divide them into A group (normal) 15;B-E group (model) 100, among them group C is atherosclerosis group、D is composite group、B is Yi Naokang foregoing group、E is YiNaokang group、F is lipitor group. At the 8th day the 100 rats of groupB、C、D、E、F would be given intraperitoneal injection of VD3 one-time and then begain to supply with high fat feed to copy AS model, at the 65th day, inject ET-1 near the MCA area except group C to copy AIS model. Observe the general condition of them, at the 74th,10 rats would be picked out randomly to draw blood so as to test (ELISA way) blood lipids and LDL、ox-LDL、ICAM、VEGF concentration, pick out 2 randomly from each group to observe the brain pathological change.
Result:
Clinical research:①Of all patients,106 patients have heart disease, occupied 19.73%,60 have coronary heart disease or angina or miocardial infarction, occupied 56.60% of all the patients with heart disease,11.55% of all the 537 patients;②NIHSS、BI、SS-QOL、TCM related scores of AIS patients with heart disease between A, B groups have no significant statistical difference (P>0.05);③Treated with TCM comprehensive method, between the AIS patients with and without heart disease, the NIHSS scores have significant statistical difference(P<0.05) at the baseline, have no significant statistical difference on the day 7th、14th、21th; the BI scores have significant statistical difference (P<0.05) on the day 60th、90th, have no significant statistical difference on the 21th day (P>0.05);SS-QOL score have no significant statistical difference on the 14th、21th day (P>0.05), have significant statistical difference(P<0.05) on the day 60th、90th; SSTCM-Severity score have no significant statistical difference on the 0th、7th day (P>0.05), have significant statistical difference(P<0.05) on the day 14th、21th、60th、90th; SSTCM-Influence on day-life have no significant statistical difference on the 0th day (P>0.05), have significant statistical difference on the day7th、14th、21th、60th、90th (P<0.05); SSTCM-Total Score have no significant statistical difference on the 0th、7th day (P>0.05), have significant statistical difference on the day 14th,21th、60th、90th(P<0.05).④The different kinds of scores of AIS patients with heart disease in the TCM comprehensive treatment group compared back and forth time all have significant statistical difference.
Experiment research:①The YiNaokang foregoing group's TCHO、TG、LDL、HDL、ApoA are significant statistically different compared with AS group. The YiNaokang foregoing group's ox-LDL、ICAM、VEGF level are significant statistically different compared with AS group, and in lowering TG、HDL, YiNaokang foregoing group and YiNaokang group are significantly statistically different compared with AS group. Chinese traditional medicine showed numerical advantage over lipitor group in reducing TCHO and TG, LDL-C.②In reducing TCHO、TG、LDL-C and rising ApoA, the YiNaokang foregoing group、YiNaokang group and lipitor group have significant statistical difference compared with AS and AIS group. YiNaokang foregoing group、YiNaokang group showed numerical advantage over lipitor group in reducing TCHO、TG and LDL-C. YiNaokang foregoing group、YiNaokang group and lipitor group have statistical significant difference compared with AS group and AIS group in lowering ox-LDL. YiNaokang foregoing group、YiNaokang group and lipitor group have significant statistical difference compared with AIS group in lowering ICAM. YiNaokang foregoing group、YiNaokang group and lipitor group have significant statistical difference compared with AS group and AIS group in VEGF level.
Conclusion:
Clinical research:①Stroke patients with higher prevalence of coronary artery disease;②The TCM comprehensive treatment doesn't show significant statistical difference compared with western medicine's basic treatment on patients with and without heart disease;③The symptoms are obviously heavier on the AIS patients with heart disease than those without heart disease in different time; The TCM comprehensive treatment show good effect on AIS patients without heart disease in the first 2 weeks, but show effect on AIS patients with heart disease after the first 2 weeks.④The TCM comprehensive treatment show good effect on the AIS patients with heart disease through comparing the different kinds of scores of AIS patients with heart disease back and forth time.
Experiment research:①YiNaokang could prevents atherosclerosis devel-opment through reducing TCHO、LDL、TG、ox-LDL、ICAM、VEGF and rising HDL、ApoA level.②YiNaokang can significantly decrease AIS SD rats's ox-LDL, ICAM and VEGF level, so it is inferred that YiNaokang's treatment effect on ischemic stroke is probably through regulating lipid metabolism and lowering ox-LDL、VEGF、ICAM in the process of atherosclerosis'formation and development.
引文
[1]王拥军主编.卒中单元.北京：科学技术文献出版社,2004.
[2]吴江.神经病学.北京：人民卫生出版社,2005.
[3]Steinberg D,Lewis A.Conner memorial lecture-oxidative modification of LDL and atherogenesis.Ci-rculation,1997,95(5):1062-1071.
[4]王庆,凌文华.C-反应蛋白与动脉粥样硬化不稳定性斑块.中山大学学报：医学科学版,2004,25(z1)：384-386.
[5]Ramos M A,Kuzuya M,Esaki T,etal.Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions.Arterioscler Thromb Vasc Biol,1998,18:1188-1196.
[6]Kim I,Moon SO.Kim SH,etal.Vascular endothelial growth factor expression of inter cellular adhesion molecule-1 (ICAM-1),vascular cell adhesion molecule 1(VCAM-1),and E-selectin through nuclear factor-κB activation in endothelial cells.J Biol Chem,2001,276:7614-20.
[7]Matsura A.Yamochi W.Hirata KI,etal.Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hpertension,1998,32(1):89-95.
[8]杨牧祥,于文涛,魏萱,等.缺血性中风患者证型分布规律的研究.中医药学刊,2006,9：1593.
[9]周慎,易振佳,刘伍立,等.757例中风后遗症中医证候与中风主症的相关性分析.湖南中医药导报,2003,8：11.
[10]马斌,高颖.中风病恢复期证候要素的研究.江苏中医药,2007,39(1)：27-29.
[11]粱伟雄,温泽淮,赖世隆,等.中风病巾医证特征与脑病理改变的相关关系研究.新中医,1999,31(7)：41-42.
[12]李士吉.中风后遗症的中医辨证论治.吉林中医药,2007,12(27)：15.
[13]包祖晓,赵国平.缺血性中风运用益气活血药的规律探讨.中医药研究,2001,6(17)：6.
[14]傅继芬.益气化瘀通脑汤治疗脑卒中82例.陕西中医,2000,21(9)：394.
[15]高建设.益气通络汤治疗缺血性脑中风213例报道.甘肃中医,2007,20(9)：23-24.
[16]俞企望.益气活血化瘀法治疗老年缺血性中风89例临床观察.中国中医基础医学杂志,2003,9(7)：75.
[17]刘茂才,黄燕,黄培新,等.涤痰祛瘀为主治疗混合性中风20例临床探讨.广州中医药大学学报,1996,13(1)：24-26.
[18]王喜芳,武继涛,许新霞.从痰瘀论治缺血性中风89例.中医研究,2007,20(8)：53.
[19]孙艺勇,张良,周成浩.活血化痰复遂胶囊治疗中风后遗症120例.陕西中医,2009,30(6)：673-674.
[20]徐寅平.化痰活血复原汤治疗急性缺血性中风60例的临床观察.北京中医,2004,13(5)：284-287.
[21]冯群法,贾明德.化痰祛瘀合剂治疗出血性脑卒中105例.湖南中医杂志,1999,15(5)：27-28.
[22]郭军平,籍玉红.化痰祛瘀治疗缺血性中风恢复期的疗效观察.中医药导报,2009,6(29)：78-79.
[23]彭方雄,彭踢.化痰通络为主治疗缺血性中风50例临床观察.时珍国医国药,2008,19(3)：725.
[24]韩玉晶,冯莹莹.化痰益气活血方治疗缺血性中风83例临床观察.中西医结合心脑血管病杂志,2007,5(6)：490-491.
[25]谢春荣,齐锡友,李连英,等.益气活血化痰蠲饮法治疗急性脑梗死疗效分析.实用中医药杂志,2008,24(2)：73-74.
[26]单大玲,杨道文,李爱科,等.益气活血化痰法治疗缺血性中风60例临床观察.中国现代医药杂志,2007,9(5)：90-91.
[27]孔祥勇,孔庆华,孙云廷.益气活血化痰通络法治疗缺血性中风96例.中国中医急症,2007,16(1)：100-101.
[28]粱元.益气活血化痰法治疗中风后遗症49例临床观察.吉林中医药,2009,29(7)：584-585.
[29]马岩梅,王海燕,彭兴华,等.益气活血化痰法治疗急性缺血性中风的临床研究.江西中医药,2006,37(10)：17-18.
[30]张云岭.运用化痰通络汤,化痰通腑汤治疗中风中经证的临床及实验研究.中国中医急症,1995,4(2)：55-57.
[31]时国臣,黄萍,刘晶等.益气活血法治疗缺血性脑卒中的临床研究.微循环学杂志,2000,10(2)：42.
[32]陆晓红,赵玉娟.益气活血法对缺血性中风高危者血浆t-PA活性的影响.天津中医药,2007,8(4)：283.
[33]王明正,梁月琴,李晓敏,等.醒脑康制剂对动物中枢缺氧和脑循环的作用.中国实验方剂学杂志,1997,3(2)：20-23.
[34]石学慧,谭涛,李丹丹.侯氏黑散治疗痰瘀阻络型缺血性中风恢复期的临床观察.中医药导报,2009,15(3)：21-23.
[35]卢峰,吴松鹰,王永.化痰活血汤对急性脑梗塞痰瘀阻络型患者D-D、FIB指标的影响.福建中医药,2009,40(5)：1-2.
[36]王大伟,张宏业,罗翌,等.益气活血法对缺血性脑卒中急性期(气虚血瘀证)神经保护作用的影响.新中医,2006,38(9)：31-32.
[37]杨晓燕,刘远新,王亮.化痰祛瘀止血汤联合西药治疗对混合性中风大鼠核转录因子-κB表达的影响.中西医结合心脑血管病杂志,2008,6(4)：428.
[38]张安玲,秦林,姚晓渝,等.益气化痰方降脂及抗凝作用的实验研究.中医研究,1997,10(3)：18-20.
[39]徐蕾,张钟爱,奚智蕾,等.丹桔胶囊对痰瘀阻络型中风先兆证患者ET-1水平的影响.白求恩军医学院学报,2005,3(4)：222.
[40]韩为,王键.益气活血化痰方对中风患者sICAM-1的影响.中医药临床杂志,2006,18(1)：44-45.
[41]韩为,王键.益气活血化痰方对脑缺血再灌注大鼠葡萄糖转运蛋白、细胞间黏附分子-1表达的影响.中医药临床杂志,2006,18(3)：252-254.
[42]张志毅,梅轶芳,赵彦萍,等.益气活血化痰法中药对泡沫细胞基质金属蛋白酶1／2mRNA表达的影响.中国中西医结合急救杂志,2005,12(4)：238-241.
[43]Judith McKay, George A. The Atlas of Heart Disease and Stroke. Geneva:World Health Organiza-tion,2004.
[44]韩炜,沈丹彤,王玉梅.华法令与阿司匹林预防老年房颤患者脑卒中的临床比较分析.南方医科大学学报,2006,26(6)：851-852.
[45]Gimbrone MA Jr, Topper JN, Nagel T, etal. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci,2000,92:230-239.
[46]孔凡斌,赵瑛,邵福源,等.急性脑卒中并发症分析.第二军医大学学报,2000,21(5)：459.
[47]Silacei P,Desgeorges A,MazzolaiL,etal.Flow pulsatility is a critical determinant of oxidative stress in endothelial cells.Hypertension,2001,38(5):1162-6.
[48]Thom T,Haase N,Rosamond W, etal. Heart disease and stroke statistics-2006 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee 2006.Circula-tion,2006,113(6):e85-e151.
[49]Wolf PA,Abbott RD,Kannel WB.Atrial fibrillation as an independent risk factor for stroke:the Framingham Study.Stroke,1991,22:983-988.
[50]Go AS, Hylek EM, Phillips KA, etal. Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention:the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA,2001,285(18):2370-75.
[51]Li C,Engstrom G,Hedblad B,etal.Blood pressure control and risk of stroke:a population-based prospective cohort study.Stroke,2005,36(4):725-730.
[52]谭振雄,吴书林.634例非心脏瓣膜病房颤患者发生脑卒中的回顾性临床总结与分析.岭南心血管病杂志,2001,7(4)：240-242.
[53]郝玉明,陈玉珍.非瓣膜病性房颤与中风.脑与神经疾病杂志,2001,9(1)：255.
[54]刘坤,纪珍花,王永久.心脏非瓣膜性房颤所致缺血性脑卒中的临床特点.齐鲁医学杂志,2007,22(3)：253-254.
[55]Goldstein LB,Adams R, Becker K,et al.Primary prevention of ischemic stroke:astatement for healthcare professionals from the Stroke Council of the American Heart Association.Stroke,2001, 32(1):280-299.
[56]Witt BJ,Brown RD Jr,Jacobsen SJ,et al.A community-based study of stroke incidence after myocardial infarction. Annals of Internal Medicine,2005,143(11):785-92.
[57]焦燕.急性脑血管意外与急性心肌梗死发病的关系.临床医学,2008,28(8)：68.
[58]杨蜀莲,张学勤,童章燕,等.心脏病与脑卒中.中华神经精神科杂志,1990,23(2)：100.
[59]刘莹,唐鸿漪.老年急性心肌梗死并发急性脑卒中22例临床分析.中国综合临床,2002,18(6)：503.
[60]唐丽荣.急性心肌梗死伴脑血管病18例分析.中华神经医学杂志,2002,1(1)：39-40.
[61]李晓杰,陈晓光,陈国俊,等.老年人急性心肌梗死合并缺血性脑卒中危险因素.黑龙江医学,2007,31(8)：570.
[62]黄晓新.60例心源性脑栓塞临床分析.河北医学,2000,6(9)：807-808.
[63]张会琴,王翠华,陈宏,等.风湿性心脏病合并脑卒中的研究.中风与神经疾病杂志,1997,14(3)：166-167.
[64]蒋柳结,彭军.急性脑卒中与脑心综合症.中风与神经疾病杂志,2003,20(5)：408.
[65]张华.急性脑卒中后脑心综合征96例临床分析.中西医结合心脑血管病杂志,2005,3(3)：268-269
[66]李晓红,李玉华,张洪检.急性脑梗塞并发心肌梗塞19例分析.临床神经病学杂志.1993,6(3)：160.
[67]徐慧琴,江淮.心脑卒中、脑心卒中与心肌梗塞、脑梗塞的临床对比研究.临床医学,1998,18(4)：33.
[68]任文波,赵清伟,白秀燕.急性心脑与脑心卒中36例分析.中华临床新医学,2003,3(8)：700-701.
[69]廖伟光,谢治惟,陈仕章.通心络胶囊联用阿司匹林对非瓣膜性心房颤动患者预防缺血性脑卒中的疗效评价.中西医结合心脑血管病杂志,2008,6(9)：1038.
[70]皮延生,张薇,施侣元,等.急性心肌梗死住院患者脑卒中危险因素的研究.中华流行病学杂志,2002,23(6)：457-460.
[71]吴兆苏.多重心血管病危险综合防治建议.中华心血管病杂志,2006,34(12)：1067-1072.
[72]卫华,王拥军.颈动脉粥样硬化与冠状动脉及主动脉粥样硬化的一致性.国外医学脑血管疾病分册,1998,6(5)：277-288.
[73]汪关宝,杨少琴,史影.中关村地区1984-2000年急性冠心病和脑卒中发病率变化趋势及影响因素探讨.实用心脑血管病杂志,2009,17(5)：366-369.
[74]陈彩萍,江渔,胡瑜,等.脂蛋白(a)与心脑血管病的相关性分析.苏州医学院学报,2000,20(4)：353-354.
[75]刘静,赵冬,秦兰萍,等.低密度脂蛋白胆固醇与心血管病发病关系的前瞻性研究.中华心血管病杂志,2001,9(29)：561-565.
[76]李贵星,袁莉,高宝秀,等.冠心病患者血清胆红素和氧化型低密度脂蛋白的相关性分析.四川医学,2008,29(12)：1702-1704.
[77]Weienberg MP,Teskens JM,Kromhout D.Yotal and high density cholesterol as risk factors for coronary heart disease in elderly men during 5 years of follow-up.The Zutphen Elderly Study.AM J Epidemiol,1996,143(2):151-158.
[78]饶明俐.中国脑血管病防治指南.摘要(一).中风与神经疾病杂志,2005,5：388-393.
[79]孙洪勇,黄健,胡小丽,等.颈动脉粥样硬化与冠心病相关性研究探讨.中国临床实用医学,2009,3(3)：73-74.
[80]Lekakis JP,Papamichael CM,Cimponeriu AT,etal.Atherosclerotic changes of extractoronary arteries are associated with the extent of coronary atherosclerosis.Am J Cardiol,2000,85(8):949-952.
[81]程洁,王根发,陈伟,等.颈动脉粥样硬化与冠心病和脑梗死的关系.上海交通大学学报(医学版),2006,26(7)：800-801.
[82]Salonen JT,Salonen R.Ultrasound B-mode imaging in observational studies of atherosclerosis progression.Circulation,1993,87(3SuppI):Ⅱ56-Ⅱ65.
[83]詹贤章,侯跃双,鲁明军.外周血管动脉粥样硬化对年轻冠心病患者的预测意义.岭南心血管病杂志,2009,15(4)：91-93.
[84]杨利,黄燕,蔡业峰,等.1418例中风患者痰瘀证候分布和演变规律探析.辽宁中医,2004,31(6)：459-460.
[85]秦秀德,张新春,周喜燕,等.中风恢复期及后遗症期方药分析.江苏中医药,2009,41(4)：55-56.
[86]蔡业峰,张新春,郭建文,等.灯盏细辛注射液治疗缺血性中风急性期随机对照试验的Meta分析.广东医学,2007,28(8)：1335-1337.
[87]肖书平,黄培新,雒晓东.脑梗塞急性期中医综合治疗对比研究.中国中医急症,2002,11(3)：160-161.
[88]蔡业峰,付于,郭建文,等.中医药治疗急性缺血中风的多中心随机对照研究.中药材,2007,30(9)：1192-1195.
[89]杨鹏远,芮耀诚,焦亚斌.动脉粥样硬化大鼠实验模型的建立.第二军医大学学报.2003.7(24)：7.
[90]顾国军,黄振兴,陶凯忠,等.HBO对内皮素-1诱导的大鼠局灶性脑缺血模型的疗效观察.第二军医大学学报,2006,27(10)：1134-1137.
[91]Zea Longa EL,Weinstein PR,Carlson S,etal.Reversible middle cerebral artery occlusion without craniectomy in rats.Stroke,1989,20:84-91.
[92]杨光华,主编.病理学.第5版.北京：人民卫生出版社,2001：126-127.
[93]Palak J, Shemanskil L, Oleary DH, etal. Relationship between incident stroke and the severity of internal carotid stenesis.Circulation.1994,90:1399-1404.
[94]李有忠,胡爱云,单秀琴.颈动脉粥样硬化与脑梗死的关系.中国超声医学杂志.1998,14：25-27.
[95]Iso H,Jacobs DR,Wentworth D,etal.Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial.New Engl J Med,1989,320:904-910. [96]Laloux P, Galanti L, Jamart J.Lipids in ischemic stroke subtypes.Acta Neurologica Belgica,2004, 104:13-19.
[97]Lindenstrom E,Boysen QNyboe J.Influence of tatal cholesterol, high density lipoprotein cholesterol, and trig lyceride on risk of cerebrovasular disease:the copenhagen city heart study.Br Med J,1994,309: 11-15.
[98]王薇,赵冬,刘静,等.中国35-64岁人群10年心血管病发病危险的前瞻性研究.中华内科杂志,2004.43：730-734.
[99]Dziedzic T,Slowik A,Gryz EA,etal.Lower serum triglyceride level is associated with increased stroke severity.Stroke,2004,35(6):151-152.
[100]周忠泉,周林,易绪英,等.187例高血压患者胆固醇、甘油三酯与脑卒中发病率关系4年随访.中国心血管病研究杂志,2007,5(6)：450-451.
[101]NotsuY,Nabika T, Park HY, etal.Evaluation of genetic risk factors for silent brain infarction.Strok-e,1999,30(9):1881-1886.
[102]Ota Y,Kugiyma K,Sugigama S.Complexes of ApoA1 with phosphatidylcholine suppress dysregulation of arterial tone by oxidized LDL.Am J Physiol,1997,273(3 pt 2):H 1215-1222.
[103]Serve PS,Dahlof B,Poulter NR,etal.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomized controlled trial. Lancet,2003,361:1149-1158.
[104]Amarenco P,Bogousslavsky J,Callahan A 3rd,etal.Stroke Prevention by Aggressive Reduction in Cholesterol Levels(SPARCL)Investigators.High-dese atorvastatin after stroke or transient ischemic attack.N Engl J Med,2006,355:549-559.
[105]罗朝淑,万英,李著华.氧化型低密度脂蛋白在动脉粥样硬化发病机理中的作用.四川生理科学杂志,2005,27(1)：23.
[106]Heinecke JW.Oxidants and antioxidants in the pathogenesis of atherosclerosis:implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis,1998,141:1-15.
[107]Steinberg D,Witztum JL.Is the oxidative modification hypothesis relevant to human atheroscleros is?Do the antioxidant trials conducted to date refute the hypothesis.Circulation,2002,105(17):2107.
[108]Sakai A,Kume N,Nishi E,etal.P-selectin and vascular cell adhesion molecule-1 are focally expression in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and Tlymphocytes.Arteriosclerosis Thromb VascBio,1997,17(2):310.
[109]高凌云,何作云,牟娇.氧化修饰低密度脂蛋白对内皮细胞功能的影响.中国微循环,2006,10(6)：399-401.
[110]Romano M,Mezzetti A,Marull C,etal. Fluvastatin reduces Soluble P-selectin and ICAM-1 Levels in hypercholesterolemic patients:role of metric oxide. J Investig Med,2000,48(3):183.
[111]Eri W,Weber PC,Weber C.Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands.Atherosclerosis,1998,136(2):297-303.
[112]Dardik R,Varon D,Tamarin I. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow condition:distinct mechanism of thrombogenic.J Thromb Haemost,2000,83(2):338-344.
[113]Calara F,Dimayugap,Niemann A. An animal model to study local oxidation of LDL and its biological effects in the arterial wall.J Arteroscler Thromb Vasc Biol,1998,18(6):884-893.
[114]陈良,张梅,李长江,等.复方丹参滴丸对动脉粥样硬化粘附因子的作用.中国动脉硬化杂志,2007,15(2)：101-104.
[115]Senger DR,Galli SJ,Dvorak AM,etal.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.Science,1983,219:983-985.
[116]Rosengart TK,Lee LY,Patel SR,etal.Angiogenesis gene therapy:phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.Circulation,1999,100:468-474.
[117]Celetti FL,Wangh JM,Amabile PG,etal.Vascular endothelial growth factor enhances atherosclerotic plaque progression.Nat Med,2001,7(4):425-429.
[118]Hunlthe J,Bokemark L,Faqerberg B.Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year old subjectively clinically healthy men.Thromb Vasc Biol,2001,21(1):101-107.
[119]粱容仙,廖仁吴,胡伟东,等.急性脑梗死患者氧化低密度脂蛋白及高敏C-反应蛋白含量变化的研究.北京医学,2007,29(9)：571.
[120]Tanne D,Haim M,Boyko V,etal.Soluble intercellular adhesion Molecule-1 and risk of future ischemic stroke:a nested case-control study from the Bezafibrate Infarction Prevention(BIP)study cohort. Stroke,2002,33(9):2182-2186.
[121]章燕幸,陈怀红,闻树群,等.急性脑梗死患者血清血管内皮生长因子的变化.中国病理生理杂志,2009,25(6)：1219-21.
[122]万鲁虹,张伟丽,孙凯,等.VEGF 2型受体基因多态与脑卒中易感性和脑卒中复发相关.中国分子心脏病学杂志,2009,9(4)：204-208.
[2]吴江.神经病学.北京：人民卫生出版社,2005.
[3]Steinberg D,Lewis A.Conner memorial lecture-oxidative modification of LDL and atherogenesis.Ci-rculation,1997,95(5):1062-1071.
[4]王庆,凌文华.C-反应蛋白与动脉粥样硬化不稳定性斑块.中山大学学报：医学科学版,2004,25(z1)：384-386.
[5]Ramos M A,Kuzuya M,Esaki T,etal.Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions.Arterioscler Thromb Vasc Biol,1998,18:1188-1196.
[6]Kim I,Moon SO.Kim SH,etal.Vascular endothelial growth factor expression of inter cellular adhesion molecule-1 (ICAM-1),vascular cell adhesion molecule 1(VCAM-1),and E-selectin through nuclear factor-κB activation in endothelial cells.J Biol Chem,2001,276:7614-20.
[7]Matsura A.Yamochi W.Hirata KI,etal.Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hpertension,1998,32(1):89-95.
[8]杨牧祥,于文涛,魏萱,等.缺血性中风患者证型分布规律的研究.中医药学刊,2006,9：1593.
[9]周慎,易振佳,刘伍立,等.757例中风后遗症中医证候与中风主症的相关性分析.湖南中医药导报,2003,8：11.
[10]马斌,高颖.中风病恢复期证候要素的研究.江苏中医药,2007,39(1)：27-29.
[11]粱伟雄,温泽淮,赖世隆,等.中风病巾医证特征与脑病理改变的相关关系研究.新中医,1999,31(7)：41-42.
[12]李士吉.中风后遗症的中医辨证论治.吉林中医药,2007,12(27)：15.
[13]包祖晓,赵国平.缺血性中风运用益气活血药的规律探讨.中医药研究,2001,6(17)：6.
[14]傅继芬.益气化瘀通脑汤治疗脑卒中82例.陕西中医,2000,21(9)：394.
[15]高建设.益气通络汤治疗缺血性脑中风213例报道.甘肃中医,2007,20(9)：23-24.
[16]俞企望.益气活血化瘀法治疗老年缺血性中风89例临床观察.中国中医基础医学杂志,2003,9(7)：75.
[17]刘茂才,黄燕,黄培新,等.涤痰祛瘀为主治疗混合性中风20例临床探讨.广州中医药大学学报,1996,13(1)：24-26.
[18]王喜芳,武继涛,许新霞.从痰瘀论治缺血性中风89例.中医研究,2007,20(8)：53.
[19]孙艺勇,张良,周成浩.活血化痰复遂胶囊治疗中风后遗症120例.陕西中医,2009,30(6)：673-674.
[20]徐寅平.化痰活血复原汤治疗急性缺血性中风60例的临床观察.北京中医,2004,13(5)：284-287.
[21]冯群法,贾明德.化痰祛瘀合剂治疗出血性脑卒中105例.湖南中医杂志,1999,15(5)：27-28.
[22]郭军平,籍玉红.化痰祛瘀治疗缺血性中风恢复期的疗效观察.中医药导报,2009,6(29)：78-79.
[23]彭方雄,彭踢.化痰通络为主治疗缺血性中风50例临床观察.时珍国医国药,2008,19(3)：725.
[24]韩玉晶,冯莹莹.化痰益气活血方治疗缺血性中风83例临床观察.中西医结合心脑血管病杂志,2007,5(6)：490-491.
[25]谢春荣,齐锡友,李连英,等.益气活血化痰蠲饮法治疗急性脑梗死疗效分析.实用中医药杂志,2008,24(2)：73-74.
[26]单大玲,杨道文,李爱科,等.益气活血化痰法治疗缺血性中风60例临床观察.中国现代医药杂志,2007,9(5)：90-91.
[27]孔祥勇,孔庆华,孙云廷.益气活血化痰通络法治疗缺血性中风96例.中国中医急症,2007,16(1)：100-101.
[28]粱元.益气活血化痰法治疗中风后遗症49例临床观察.吉林中医药,2009,29(7)：584-585.
[29]马岩梅,王海燕,彭兴华,等.益气活血化痰法治疗急性缺血性中风的临床研究.江西中医药,2006,37(10)：17-18.
[30]张云岭.运用化痰通络汤,化痰通腑汤治疗中风中经证的临床及实验研究.中国中医急症,1995,4(2)：55-57.
[31]时国臣,黄萍,刘晶等.益气活血法治疗缺血性脑卒中的临床研究.微循环学杂志,2000,10(2)：42.
[32]陆晓红,赵玉娟.益气活血法对缺血性中风高危者血浆t-PA活性的影响.天津中医药,2007,8(4)：283.
[33]王明正,梁月琴,李晓敏,等.醒脑康制剂对动物中枢缺氧和脑循环的作用.中国实验方剂学杂志,1997,3(2)：20-23.
[34]石学慧,谭涛,李丹丹.侯氏黑散治疗痰瘀阻络型缺血性中风恢复期的临床观察.中医药导报,2009,15(3)：21-23.
[35]卢峰,吴松鹰,王永.化痰活血汤对急性脑梗塞痰瘀阻络型患者D-D、FIB指标的影响.福建中医药,2009,40(5)：1-2.
[36]王大伟,张宏业,罗翌,等.益气活血法对缺血性脑卒中急性期(气虚血瘀证)神经保护作用的影响.新中医,2006,38(9)：31-32.
[37]杨晓燕,刘远新,王亮.化痰祛瘀止血汤联合西药治疗对混合性中风大鼠核转录因子-κB表达的影响.中西医结合心脑血管病杂志,2008,6(4)：428.
[38]张安玲,秦林,姚晓渝,等.益气化痰方降脂及抗凝作用的实验研究.中医研究,1997,10(3)：18-20.
[39]徐蕾,张钟爱,奚智蕾,等.丹桔胶囊对痰瘀阻络型中风先兆证患者ET-1水平的影响.白求恩军医学院学报,2005,3(4)：222.
[40]韩为,王键.益气活血化痰方对中风患者sICAM-1的影响.中医药临床杂志,2006,18(1)：44-45.
[41]韩为,王键.益气活血化痰方对脑缺血再灌注大鼠葡萄糖转运蛋白、细胞间黏附分子-1表达的影响.中医药临床杂志,2006,18(3)：252-254.
[42]张志毅,梅轶芳,赵彦萍,等.益气活血化痰法中药对泡沫细胞基质金属蛋白酶1／2mRNA表达的影响.中国中西医结合急救杂志,2005,12(4)：238-241.
[43]Judith McKay, George A. The Atlas of Heart Disease and Stroke. Geneva:World Health Organiza-tion,2004.
[44]韩炜,沈丹彤,王玉梅.华法令与阿司匹林预防老年房颤患者脑卒中的临床比较分析.南方医科大学学报,2006,26(6)：851-852.
[45]Gimbrone MA Jr, Topper JN, Nagel T, etal. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci,2000,92:230-239.
[46]孔凡斌,赵瑛,邵福源,等.急性脑卒中并发症分析.第二军医大学学报,2000,21(5)：459.
[47]Silacei P,Desgeorges A,MazzolaiL,etal.Flow pulsatility is a critical determinant of oxidative stress in endothelial cells.Hypertension,2001,38(5):1162-6.
[48]Thom T,Haase N,Rosamond W, etal. Heart disease and stroke statistics-2006 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee 2006.Circula-tion,2006,113(6):e85-e151.
[49]Wolf PA,Abbott RD,Kannel WB.Atrial fibrillation as an independent risk factor for stroke:the Framingham Study.Stroke,1991,22:983-988.
[50]Go AS, Hylek EM, Phillips KA, etal. Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention:the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA,2001,285(18):2370-75.
[51]Li C,Engstrom G,Hedblad B,etal.Blood pressure control and risk of stroke:a population-based prospective cohort study.Stroke,2005,36(4):725-730.
[52]谭振雄,吴书林.634例非心脏瓣膜病房颤患者发生脑卒中的回顾性临床总结与分析.岭南心血管病杂志,2001,7(4)：240-242.
[53]郝玉明,陈玉珍.非瓣膜病性房颤与中风.脑与神经疾病杂志,2001,9(1)：255.
[54]刘坤,纪珍花,王永久.心脏非瓣膜性房颤所致缺血性脑卒中的临床特点.齐鲁医学杂志,2007,22(3)：253-254.
[55]Goldstein LB,Adams R, Becker K,et al.Primary prevention of ischemic stroke:astatement for healthcare professionals from the Stroke Council of the American Heart Association.Stroke,2001, 32(1):280-299.
[56]Witt BJ,Brown RD Jr,Jacobsen SJ,et al.A community-based study of stroke incidence after myocardial infarction. Annals of Internal Medicine,2005,143(11):785-92.
[57]焦燕.急性脑血管意外与急性心肌梗死发病的关系.临床医学,2008,28(8)：68.
[58]杨蜀莲,张学勤,童章燕,等.心脏病与脑卒中.中华神经精神科杂志,1990,23(2)：100.
[59]刘莹,唐鸿漪.老年急性心肌梗死并发急性脑卒中22例临床分析.中国综合临床,2002,18(6)：503.
[60]唐丽荣.急性心肌梗死伴脑血管病18例分析.中华神经医学杂志,2002,1(1)：39-40.
[61]李晓杰,陈晓光,陈国俊,等.老年人急性心肌梗死合并缺血性脑卒中危险因素.黑龙江医学,2007,31(8)：570.
[62]黄晓新.60例心源性脑栓塞临床分析.河北医学,2000,6(9)：807-808.
[63]张会琴,王翠华,陈宏,等.风湿性心脏病合并脑卒中的研究.中风与神经疾病杂志,1997,14(3)：166-167.
[64]蒋柳结,彭军.急性脑卒中与脑心综合症.中风与神经疾病杂志,2003,20(5)：408.
[65]张华.急性脑卒中后脑心综合征96例临床分析.中西医结合心脑血管病杂志,2005,3(3)：268-269
[66]李晓红,李玉华,张洪检.急性脑梗塞并发心肌梗塞19例分析.临床神经病学杂志.1993,6(3)：160.
[67]徐慧琴,江淮.心脑卒中、脑心卒中与心肌梗塞、脑梗塞的临床对比研究.临床医学,1998,18(4)：33.
[68]任文波,赵清伟,白秀燕.急性心脑与脑心卒中36例分析.中华临床新医学,2003,3(8)：700-701.
[69]廖伟光,谢治惟,陈仕章.通心络胶囊联用阿司匹林对非瓣膜性心房颤动患者预防缺血性脑卒中的疗效评价.中西医结合心脑血管病杂志,2008,6(9)：1038.
[70]皮延生,张薇,施侣元,等.急性心肌梗死住院患者脑卒中危险因素的研究.中华流行病学杂志,2002,23(6)：457-460.
[71]吴兆苏.多重心血管病危险综合防治建议.中华心血管病杂志,2006,34(12)：1067-1072.
[72]卫华,王拥军.颈动脉粥样硬化与冠状动脉及主动脉粥样硬化的一致性.国外医学脑血管疾病分册,1998,6(5)：277-288.
[73]汪关宝,杨少琴,史影.中关村地区1984-2000年急性冠心病和脑卒中发病率变化趋势及影响因素探讨.实用心脑血管病杂志,2009,17(5)：366-369.
[74]陈彩萍,江渔,胡瑜,等.脂蛋白(a)与心脑血管病的相关性分析.苏州医学院学报,2000,20(4)：353-354.
[75]刘静,赵冬,秦兰萍,等.低密度脂蛋白胆固醇与心血管病发病关系的前瞻性研究.中华心血管病杂志,2001,9(29)：561-565.
[76]李贵星,袁莉,高宝秀,等.冠心病患者血清胆红素和氧化型低密度脂蛋白的相关性分析.四川医学,2008,29(12)：1702-1704.
[77]Weienberg MP,Teskens JM,Kromhout D.Yotal and high density cholesterol as risk factors for coronary heart disease in elderly men during 5 years of follow-up.The Zutphen Elderly Study.AM J Epidemiol,1996,143(2):151-158.
[78]饶明俐.中国脑血管病防治指南.摘要(一).中风与神经疾病杂志,2005,5：388-393.
[79]孙洪勇,黄健,胡小丽,等.颈动脉粥样硬化与冠心病相关性研究探讨.中国临床实用医学,2009,3(3)：73-74.
[80]Lekakis JP,Papamichael CM,Cimponeriu AT,etal.Atherosclerotic changes of extractoronary arteries are associated with the extent of coronary atherosclerosis.Am J Cardiol,2000,85(8):949-952.
[81]程洁,王根发,陈伟,等.颈动脉粥样硬化与冠心病和脑梗死的关系.上海交通大学学报(医学版),2006,26(7)：800-801.
[82]Salonen JT,Salonen R.Ultrasound B-mode imaging in observational studies of atherosclerosis progression.Circulation,1993,87(3SuppI):Ⅱ56-Ⅱ65.
[83]詹贤章,侯跃双,鲁明军.外周血管动脉粥样硬化对年轻冠心病患者的预测意义.岭南心血管病杂志,2009,15(4)：91-93.
[84]杨利,黄燕,蔡业峰,等.1418例中风患者痰瘀证候分布和演变规律探析.辽宁中医,2004,31(6)：459-460.
[85]秦秀德,张新春,周喜燕,等.中风恢复期及后遗症期方药分析.江苏中医药,2009,41(4)：55-56.
[86]蔡业峰,张新春,郭建文,等.灯盏细辛注射液治疗缺血性中风急性期随机对照试验的Meta分析.广东医学,2007,28(8)：1335-1337.
[87]肖书平,黄培新,雒晓东.脑梗塞急性期中医综合治疗对比研究.中国中医急症,2002,11(3)：160-161.
[88]蔡业峰,付于,郭建文,等.中医药治疗急性缺血中风的多中心随机对照研究.中药材,2007,30(9)：1192-1195.
[89]杨鹏远,芮耀诚,焦亚斌.动脉粥样硬化大鼠实验模型的建立.第二军医大学学报.2003.7(24)：7.
[90]顾国军,黄振兴,陶凯忠,等.HBO对内皮素-1诱导的大鼠局灶性脑缺血模型的疗效观察.第二军医大学学报,2006,27(10)：1134-1137.
[91]Zea Longa EL,Weinstein PR,Carlson S,etal.Reversible middle cerebral artery occlusion without craniectomy in rats.Stroke,1989,20:84-91.
[92]杨光华,主编.病理学.第5版.北京：人民卫生出版社,2001：126-127.
[93]Palak J, Shemanskil L, Oleary DH, etal. Relationship between incident stroke and the severity of internal carotid stenesis.Circulation.1994,90:1399-1404.
[94]李有忠,胡爱云,单秀琴.颈动脉粥样硬化与脑梗死的关系.中国超声医学杂志.1998,14：25-27.
[95]Iso H,Jacobs DR,Wentworth D,etal.Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial.New Engl J Med,1989,320:904-910. [96]Laloux P, Galanti L, Jamart J.Lipids in ischemic stroke subtypes.Acta Neurologica Belgica,2004, 104:13-19.
[97]Lindenstrom E,Boysen QNyboe J.Influence of tatal cholesterol, high density lipoprotein cholesterol, and trig lyceride on risk of cerebrovasular disease:the copenhagen city heart study.Br Med J,1994,309: 11-15.
[98]王薇,赵冬,刘静,等.中国35-64岁人群10年心血管病发病危险的前瞻性研究.中华内科杂志,2004.43：730-734.
[99]Dziedzic T,Slowik A,Gryz EA,etal.Lower serum triglyceride level is associated with increased stroke severity.Stroke,2004,35(6):151-152.
[100]周忠泉,周林,易绪英,等.187例高血压患者胆固醇、甘油三酯与脑卒中发病率关系4年随访.中国心血管病研究杂志,2007,5(6)：450-451.
[101]NotsuY,Nabika T, Park HY, etal.Evaluation of genetic risk factors for silent brain infarction.Strok-e,1999,30(9):1881-1886.
[102]Ota Y,Kugiyma K,Sugigama S.Complexes of ApoA1 with phosphatidylcholine suppress dysregulation of arterial tone by oxidized LDL.Am J Physiol,1997,273(3 pt 2):H 1215-1222.
[103]Serve PS,Dahlof B,Poulter NR,etal.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomized controlled trial. Lancet,2003,361:1149-1158.
[104]Amarenco P,Bogousslavsky J,Callahan A 3rd,etal.Stroke Prevention by Aggressive Reduction in Cholesterol Levels(SPARCL)Investigators.High-dese atorvastatin after stroke or transient ischemic attack.N Engl J Med,2006,355:549-559.
[105]罗朝淑,万英,李著华.氧化型低密度脂蛋白在动脉粥样硬化发病机理中的作用.四川生理科学杂志,2005,27(1)：23.
[106]Heinecke JW.Oxidants and antioxidants in the pathogenesis of atherosclerosis:implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis,1998,141:1-15.
[107]Steinberg D,Witztum JL.Is the oxidative modification hypothesis relevant to human atheroscleros is?Do the antioxidant trials conducted to date refute the hypothesis.Circulation,2002,105(17):2107.
[108]Sakai A,Kume N,Nishi E,etal.P-selectin and vascular cell adhesion molecule-1 are focally expression in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and Tlymphocytes.Arteriosclerosis Thromb VascBio,1997,17(2):310.
[109]高凌云,何作云,牟娇.氧化修饰低密度脂蛋白对内皮细胞功能的影响.中国微循环,2006,10(6)：399-401.
[110]Romano M,Mezzetti A,Marull C,etal. Fluvastatin reduces Soluble P-selectin and ICAM-1 Levels in hypercholesterolemic patients:role of metric oxide. J Investig Med,2000,48(3):183.
[111]Eri W,Weber PC,Weber C.Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands.Atherosclerosis,1998,136(2):297-303.
[112]Dardik R,Varon D,Tamarin I. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow condition:distinct mechanism of thrombogenic.J Thromb Haemost,2000,83(2):338-344.
[113]Calara F,Dimayugap,Niemann A. An animal model to study local oxidation of LDL and its biological effects in the arterial wall.J Arteroscler Thromb Vasc Biol,1998,18(6):884-893.
[114]陈良,张梅,李长江,等.复方丹参滴丸对动脉粥样硬化粘附因子的作用.中国动脉硬化杂志,2007,15(2)：101-104.
[115]Senger DR,Galli SJ,Dvorak AM,etal.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.Science,1983,219:983-985.
[116]Rosengart TK,Lee LY,Patel SR,etal.Angiogenesis gene therapy:phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.Circulation,1999,100:468-474.
[117]Celetti FL,Wangh JM,Amabile PG,etal.Vascular endothelial growth factor enhances atherosclerotic plaque progression.Nat Med,2001,7(4):425-429.
[118]Hunlthe J,Bokemark L,Faqerberg B.Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year old subjectively clinically healthy men.Thromb Vasc Biol,2001,21(1):101-107.
[119]粱容仙,廖仁吴,胡伟东,等.急性脑梗死患者氧化低密度脂蛋白及高敏C-反应蛋白含量变化的研究.北京医学,2007,29(9)：571.
[120]Tanne D,Haim M,Boyko V,etal.Soluble intercellular adhesion Molecule-1 and risk of future ischemic stroke:a nested case-control study from the Bezafibrate Infarction Prevention(BIP)study cohort. Stroke,2002,33(9):2182-2186.
[121]章燕幸,陈怀红,闻树群,等.急性脑梗死患者血清血管内皮生长因子的变化.中国病理生理杂志,2009,25(6)：1219-21.
[122]万鲁虹,张伟丽,孙凯,等.VEGF 2型受体基因多态与脑卒中易感性和脑卒中复发相关.中国分子心脏病学杂志,2009,9(4)：204-208.